Bevacizumab 1 — Class II drug recall D-0581-2016
Terminated recall by Pine Pharmaceuticals, LLC, reported 2016-01-27, distributed nationwide. Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitrea
| Recall number | D-0581-2016 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pine Pharmaceuticals, LLC, Tonawanda, NY, United States |
| Recall initiated | 2015-11-04 |
| Classified | 2016-01-20 |
| Reported by FDA | 2016-01-27 |
| Terminated | 2017-03-22 |
| Distributed | Nationwide (US) |
| Reason classes | specification failure |
| Expiration dates | 2015-11-04, 2015-11-05, 2015-11-08, 2015-11-09, 2015-11-10, 2015-11-11, 2015-11-12, 2015-11-15, 2015-11-16, 2015-11-17, 2015-11-18, 2015-11-19, 2015-11-22, 2015-11-23, 2015-11-24, 2015-11-25, 2015-11-26, 2015-11-29, 2015-11-30, 2015-12-01, 2015-12-02, 2015-12-03, 2015-12-07, 2015-12-08, 2015-12-09 and 37 more |
Product
Bevacizumab 1.25 mg/0.05 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal Rx -- Pine Pharmaceuticals, 100 Colvin Woods Pkwy Suite 300, Tonawanda, NY 14150.
Reason for recall
Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0581-2016. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.